Moderna (MRNA) Enterprise Value (2018 - 2026)

Moderna (MRNA) has reported Enterprise Value for 9 consecutive years, with $22.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 307.1% year-over-year to $22.8 billion in Q2 2026; TTM through Jun 2026 was $22.8 billion, a 307.1% increase from a year earlier, with the FY2025 full-year figure at $5.8 billion, down 35.51% from the prior year.
• Enterprise Value was $22.8 billion for Q2 2026 at Moderna, up from $15.0 billion in the prior quarter.
• Over five years, Enterprise Value peaked at $59.3 billion in Q4 2022 and troughed at $5.0 billion in Q1 2025.
• A 5-year average of $28.3 billion and a median of $30.6 billion in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value slumped 84.91% in 2025 and soared 307.1% in 2026, its largest moves.
• Over 5 years, Enterprise Value stood at $59.3 billion in 2022, then slumped by 50.4% to $29.4 billion in 2023, then tumbled by 69.29% to $9.0 billion in 2024, then sank by 35.51% to $5.8 billion in 2025, then surged by 291.82% to $22.8 billion in 2026.
• The last three Enterprise Value figures came in at $22.8 billion (Q2 2026), $15.0 billion (Q1 2026), and $5.8 billion (Q4 2025), per Business Quant data.